Core Insights - The core viewpoint of the articles highlights the significant role of AI health applications, particularly the upgraded "Ant Fortune" app, in transforming healthcare consultations, especially in the context of pregnancy-related inquiries and enhancing male participation in the process [1][3]. Group 1: AI Health Application Development - The "Ant Fortune" app has over 15 million monthly active users, with approximately 55% from lower-tier cities, showcasing its inclusive nature [1]. - AI applications are increasingly seen as a solution to repetitive inquiries in healthcare, with 70% of offline consultations related to basic lifestyle questions during pregnancy [3]. - The app has attracted 160,000 consultations for its AI avatar of Dr. Duan Tao, a prominent obstetrician, indicating a growing acceptance of AI in healthcare [3]. Group 2: Market Potential and Strategic Moves - The Chinese health industry is projected to exceed 20 trillion RMB by 2025, presenting a significant opportunity for AI health management applications [3]. - Ant Group has upgraded its "Digital Health Division" to a "Health Business Group," emphasizing its commitment to the health sector as a strategic pillar [3]. - The competition in the AI health application space is intensifying, with tech companies vying for data entry points from both hospitals and patients to convert infrequent medical interactions into frequent health consultations [4]. Group 3: Investment and Innovation - The AI medical sector has seen active financing, with companies like Noah AI and SenseTime Medical securing substantial funding, indicating investor confidence in the sector's growth potential [4]. - Despite the funding activity, many AI medical companies have yet to establish clear profit pathways, necessitating the development of competitive and differentiated products to justify their valuations [5]. - Experts emphasize the need for AI tools to evolve beyond simple assistance to become integral to the healthcare system, requiring the accumulation of complex data for improved problem-solving capabilities [5].

高质量职场健康管理的核心逻辑，是推动企业健康管理实现三大转变：从"事后理赔"转向"事前预防"、 从"普适福利"转向"精准干预"、从"成本中心"转向"价值创造"。这套体系的价值在于其可定制化和可扩 展性。无论是上海的服务业、南京的制造业，还是广州的高科技企业，高质量职场健康管理都能根据其 行业特性和员工结构，提供适配的解决方案——这正是国家级试点项目寻求的，能在不同场景下验证并 推广的模式。 本文源自：格隆汇 消息面上，一场名为"全国防控重大慢病创新融合试点项目——高质量职场健康管理先行试点工作"的系 列宣讲会，从10月底迄今，先后在上海、南京、广州展开。这不仅是一系列会议，更是国家层面试图系 统性解决职场健康问题的重要实践。国家级项目选择平安，源于其独一无二的 "金融+医疗"综合服务能 力。在覆盖华东、华南的试点工作中，平安将具体扮演着资源整合者、数据赋能者及模式共创者三重关 键角色。 12月15日，港股三大指数今日全线下跌，互联网医疗板块的头部企业中，仅平安好医生(1833.HK)一枝 独秀，逆势涨超6%。 ...

Core Viewpoint - The Hong Kong stock market indices experienced a decline, but Ping An Good Doctor (1833.HK) stood out by rising over 6%, driven by its involvement in a national health management initiative aimed at addressing workplace health issues [1] Group 1: Company Performance - Ping An Good Doctor was the only leading company in the internet healthcare sector to show a positive performance amidst a market downturn, with a rise of over 6% [1] Group 2: National Health Initiative - A series of seminars titled "National Major Chronic Disease Prevention and Control Innovation Integration Pilot Project" has been held in Shanghai, Nanjing, and Guangzhou since the end of October, indicating a systematic approach by the government to tackle workplace health issues [1] - The selection of Ping An for this national project is attributed to its unique "finance + healthcare" integrated service capability, positioning it as a key player in resource integration, data empowerment, and model co-creation [1] Group 3: Health Management Transformation - The core logic of high-quality workplace health management is to shift from "post-claim" to "prevention," from "universal benefits" to "precise intervention," and from "cost center" to "value creation" [1] - The value of this health management system lies in its customizability and scalability, allowing it to provide tailored solutions based on the industry characteristics and employee structure of different sectors such as service, manufacturing, and high-tech [1]

Group 1 - The core viewpoint of the news is that Ping An Good Doctor (01833) has seen a stock price increase of over 5%, reaching HKD 14.32, with a trading volume of HKD 264 million, following its recognition in a national health management initiative [1] - The company was awarded as one of the first high-quality workplace health management pilot units due to its extensive experience and high-quality service capabilities in corporate health management [1] - The selection of Ping An for this national project is attributed to its unique "finance + healthcare" integrated service capability, which is a key output of its corporate health strategy [1] Group 2 - In the pilot projects covering East and South China, the company will provide a seamless service experience for employees of participating enterprises, including online consultations, expert appointments, and offline medical coordination [2] - The company will utilize artificial intelligence and big data technology to assist enterprises in building electronic health records for employees and establishing disease risk warning models, transforming "vague management" into "precise profiling" [2] - The company aims to explore innovative mechanisms linking "health management outcomes" with "insurance cost" in collaboration with pilot enterprises, validating the feasibility of optimizing overall welfare investment through health behavior incentives [2]

大会上，京东健康联合中国抗癌协会发起"肿瘤整合防治工程(2025-2030)"，构建"防-筛-诊-治-康"全流程体系，将AI等前沿技术深度融合于临床实践，探索 肿瘤防治的中国路径。京东健康还分别与广州医科大学附属第一医院、中山大学孙逸仙纪念医院、北京大学肿瘤医院的相应课题组进行AI专病课题合作签 约，持续引领肿瘤诊疗模式系统性革新，为专科专病医学实践与患者管理注入科技动力。 做深做专：共建专病专科大模型新标杆 智通财经APP获悉，近日，2025肿瘤防治新进展大会在京举行。会上，京东健康(06618)宣布，旗下"京医千询"医疗大模型持续强化专病专科赋能能力，已实 现从通用基座模型到全科大模型，再到专科专病大模型的完整技术演进，目前正与国内顶级医疗机构合作，持续研发涵盖大部分常见肿瘤和重大慢性病的专 科专病大模型。 在患者管理层面，AI技术实现了肿瘤全周期精细化管理，通过智能随访、康复指导、便捷复诊等服务，提升患者随访依从性，减少重复咨询，让院外管理 更高效、更精准。同时，通过健康档案大数据整合，为患者提供个性化健康管理方案，推动肿瘤防治从疾病治疗向全周期健康管理转变。 未来，京东健康将持续在认知闭环进化系统、跨 ...

本报讯 （记者梁傲男）12月13日，由中国抗癌协会与京东健康共同发起的肿瘤整合防治工程正式启 动，同期，2025肿瘤防治新进展大会在京举行。 大会汇聚由中国工程院院士、中国抗癌协会理事长樊代明领衔的顶尖专家阵容，聚焦肿瘤领域学术新进 展、医工交叉新技术、专病大模型及科研成果转化等前沿和热点议题，打造了一场肿瘤防治的学术盛 宴。 京 东供图 在肿瘤专科建设及专病防治方面，依然存在医疗资源分布不均、临床决策复杂、科研转化滞后、患者管 理低效等系统性挑战。 京东健康医疗及AI应用平台部负责人表示，京东健康依托京医千询大模型，全面加速"医检诊药"闭环， 打造AI京医专业服务智能体、专家医生智能体、RWD科研平台，以医疗级AI为目标，形成资源可及、 决策可依、科研可转化、患者可管理的智能肿瘤防治体系，为医生赋能、为患者服务、为行业提效。 京东集团SEC委员、京东健康CEO曹冬表示，作为中国肿瘤防治事业的参与者和推动者，京东健康始终 坚持"以专业守护生命"的理念，携手中国抗癌协会等权威机构，系统推进从科普教育、早筛早诊到规范 诊疗、康复管理的全程服务，切实守护大众健康。未来，京东健康将持续与各方合作伙伴并肩，深化人 工智 ...

目前，京东互联网医院肿瘤专科已全面升级，通过权威三甲医院专家团队与AI智能技术结合，构建"筛 查、诊断、治疗、随访"一体化服务体系。据悉，该肿瘤专科已有3万余名三甲医院权威专家。 会上，京东健康分别与广州医科大学附属第一医院、中山大学孙逸仙纪念医院、北京大学肿瘤医院进行 AI专病课题合作签约。聚焦消化道肿瘤、前列腺癌及呼吸系统等方向，京东健康将基于京医千询大模 型技术能力，携手三大医疗机构围绕AI在影像识别、病情动态监测与辅助诊疗等方面的创新应用与前 沿进展进行深度合作。 新浪科技讯 12月14日上午消息，昨日，在2025肿瘤防治新进展大会上，京东健康与中国抗癌协会共同 发起"肿瘤整合防治工程（2025-2030）"，构建"防-筛-诊-治-康"全流程体系，将AI等前沿技术深度融合 于临床实践，探索肿瘤防治的中国路径。 针对肿瘤科普内容真伪难辨、大众对肿瘤早筛重视不足等痛点，京东健康与中国抗癌协会将推出肿瘤防 治科普行动；围绕医疗资源均衡可及、基层医院专科建设等需求，双方将推出肿瘤医生赋能计划；此 外，双方还将开展肿瘤康复技术产学研合作。 京东健康医疗及AI应用平台部负责人表示，京东健康依托京医千询大模型，全面 ...

证券之星消息，12月12日南向资金减持99.25万股京东健康（06618.HK）。近5个交易日中，获南向资金 减持的有5天，累计净减持704.93万股。近20个交易日中，获南向资金减持的有14天，累计净减持 1253.46万股。截至目前，南向资金持有京东健康（06618.HK）2.67亿股，占公司已发行普通股的 8.32%。 京东健康股份有限公司是一家主要提供医药和健康产品、互联网医疗健康服务、健康管理及智能医疗健 康解决方案的投资控股公司。该公司业务主要包括零售药房和医疗健康服务。零售药房业务主要通过自 营及在线平台和即时零售渠道销售医药和健康产品以及医疗器械。医疗健康服务业务主要通过互联网医 院和医疗大模型提供医疗健康服务。该公司还提供广告投放等线上营销服务。该公司主要在国内市场开 展业务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

12月12日，港股三大指数集体大涨。其中，恒生指数收涨1.75%，报25976.79点，恒生科技指数涨1.87%，恒生中国企业指数涨1.62%。全日大市成交额为 2427亿港元，南向资金净卖出52.87亿港元。 【导读】重磅合作，阿里健康大涨！国际机构唱多，网易大涨 | 序号 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 | 成交额 | 年初至今 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | HSI | 恒生指数 | 25976.79c | 446.28 | 1.75% | 2427亿 | 29.50% | | 2 | HSTECH | 恒生科技 | 5638.05c | 103.46 | 1.87% | 765亿 | 26.18% | | 3 | HSBIO | 恒生生物科技 | 15267.73c | 217.74 | 1.45% | 129亿 | 77.09% | | ব | HSCEI | 恒生中国企业指数 | 9079.35c | 145.07 | 1.62% | 951亿 | 24.55% | | 5 | HSCI | 恒 ...

【导读】 重磅合作，阿里健康大涨！国际机构唱多，网易大涨 中国基金报记者 格林 12 月 12 日，港股三大指数集体大涨。其中，恒生指数收涨 1.75% ，报 25976.79 点，恒生科技指数涨 1.87% ，恒生中国企业指数涨 1.62% 。全日大市成交额为 2427 亿港元，南向资金净卖出 52.87 亿港元。 | 序号 | 代码 | 名称 | 现价 | 涨跌 | 涨跌幅 | 成交额 | 年初至今 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | HSI | 恒生指数 | 25976.79c | 446.28 | 1.75% | 2427亿 | 29.50% | | 2 | HSTECH | 恒生科技 | 5638.05c | 103.46 | 1.87% | 765亿 | 26.18% | | 3 | HSBIO | 恒生生物科技 | 15267.73c | 217.74 | 1.45% | 129亿 | 77.09% | | 4 | HSCEI | 恒生中国企业指数 | 9079.35c | 145.07 | 1.62% | 951亿 ...